Kim A. Boggess is Professor of Ob/Gyn and Maternal Fetal Medicine at the University of North Carolina at Chapel Hill. Her clinical and research expertise focuses on infection and inflammation complicating pregnancy. Her prior accomplishments include preclinical and clinical studies defining the relationship between maternal oral infection, inflammation, and adverse pregnancy outcomes.

Dr. Boggess has successfully managed and conducted multi-center trials, funded by both the National Institutes of Health and by industry. She was co-investigator of a multicenter clinical study to determine the optimal antibiotic strategy to prevent maternal and infant post-cesarean infectious complications, Principal Investigator for a longitudinal study of markers for preeclampsia and spontaneous preterm birth, and Principal Investigator of a pharmacokinetic study of 17-hydroxyprogesterone for preterm birth prevention. She has also completed research using large databases, including a MarketScan® Claims Database analysis of the association of treatment choice in gestational diabetes on adverse pregnancy outcomes and an examination of the utility of Tdap vaccination during pregnancy. Currently, she is Co-Investigator for an NHLBI-funded multicenter trial of hypertension treatment complicating pregnancy and the Co-Principal Investigator for an NICHD-funded multicenter trial of treatment of type 2 diabetes in pregnancy.

Dr. Boggess completed her MD training at the State University of Stony Brook, her Ob/Gyn residency training at the University of Washington, her Maternal Fetal Medicine Fellowship training at Duke University, and her Certificate in Health Disparities Research at the University of North Carolina at Chapel Hill.